Antibiotic Stewardship
Vaughn V, Giesler D, Mashrah D, et al. Pharmacist gender and physician acceptance of antibiotic stewardship recommendations: An analysis of the reducing overuse of antibiotics at discharge home intervention. Infection Control & Hospital Epidemiology, 1-8. Abstract
Pneumonia
Haas MK, Dalton K, Knepper BC, et al. Effects of a Syndrome Specific Antibiotic Stewardship Intervention for Inpatient Community Acquired Pneumonia. Open Forum Infect Dis. 2016:3(4).ofw186 Abstract
Li DX, et al. Sustained Impact of an Antimicrobial Intervention for Community-Acquired Pneumonia. Infect Control Hosp Epidemiol 2016; 37:1243-1246. Abstract
Unranga A, Espana P, Bilbao, et al. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. JAMA Intern Med. 2016;176(9):1257-65. Abstract
Chalmers J, et al. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 2014; 58:330-9. Abstract
Chen JI, et al. Outcomes of healthcare-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline –concordant regimens for patients admitted to acute care wards from home. Ann Pharmacother; 47(1):9-19. Abstract
Avdic E, Cuschinotto LA, Hughes AH, et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis 2012;54 (11):1581-7. Abstract
Labelle AJ, et al. A comparison of culture –positive and culture negative healthcare-associated pneumonia. Chest 2010;137: 1130-1137. Abstract
Schlueter M, et al. Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia. Infection 2010; 38:357-62. Abstract
Dimopoulos G, Mathaiou DK, et al. Short versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs. 2008;68(13):1841-54. Abstract
Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007;120 (9):783-90. Abstract
File TM Jr. Mandell LA, et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicenter, double-blind study. J Antimicrob Chemother 2007;60:112-20. Abstract
Moussaoui R, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community-acquired pneumonia: randomized, double blind study. BMJ 2006;332:1335. Abstract
Dunbar LM, Wunderink RG et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-60. Abstract
Leophante P, Choutet P, Gaillat J, et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Med Mal Infect 2002;32:369-81. Abstract